A Global Cell Therapy CDMO Focused On Accelerating The Delivery Of Innovative Cell Therapies

BioCentriq is a global cell therapy Contract Development and Manufacturing Organization (CDMO) with a proven track record successfully transferring, developing, and manufacturing GMP drug product for use in clinical trials. The Executive, Technical, and Business Development teams have commercialized four unique cell therapies and translated more than 20 programs into the clinic. This expertise, coupled with phase-appropriate quality systems and a modern infrastructure have established BioCentriq as a trusted strategic partner for the development and manufacture of autologous and allogeneic cell therapies. BioCentriq’s four flexible GMP manufacturing suites are supported by fully equipped process and analytical development laboratories to ensure seamless translation from the lab to the clinic.

In May 2022, BioCentriq was purchased by GC Holdings Inc. of South Korea for $73 million. As an integral member of the GC global network, through teamwork and collaboration, BioCentriq and GC Cell offer harmonized CDMO services to facilitate seamless cross-border technology transfers to improve access to and reduce the cost of life-changing cell therapies. In June 2023, BioCentriq launched its LEAP™ Advanced Therapy Platform designed to help cell therapy developers move from contract to clinic in as little as six months.

Download the deck to gain insight into BioCentriq as a collaborative CDMO specializing in cell and gene therapies. Learn more about the company, their capabilities, and their leadership team.